Click here if you are having trouble viewing this message. Pichia pastoris Protein Expression Excellence New Dimensions - Protein Yields of up to 35 g/L VTU Pichia processes show exceptionally high space-time yields with typical product concentrations of 10 - 20 g/L and very high initial purities of 80 - 90 % in the culture supernatant. Since its foundation 2008, VTU´s highly skilled team has been continuously optimizing and expanding its Pichia technology platform to generate an unparalleled spectrum of expression tools and ingenious expression strategies leading to a high performance technology platform to meet highly specific expression needs. Recently, VTU developed an expression strain capable of producing 35 g/L of recombinant mouse serum albumin. Based on this achievement, we assume that the biological limit of Pichia pastoris has not yet been reached so far holding potential for further optimization. VTU´s Track Record VTU´s cutting-edge technologies paired with VTU´s qualified staff provide our customers with industrial high-performance expression strains capable of expressing a wide range of biologics and other proteins with or without methanol induction. High Productivities - Even Without Methanol In a recent case study VTU´s broad and versatile Pichia pastoris protein production platform hit the 20 g/L mark in methanol-free protein production. VTU´s unique methanol-free Pichia system - strong expression and further advantages such as   abolishing toxic and explosive methanol glycerol or glucose as the sole carbon source lower production costs due to reduced cooling demand and shortened process time Please follow this link for more information NEW - Custom Glycoprotein Production VTU´s high-yielding Pichia platform combined with Pichia Glycoswitch® This unique combination of technologies acting synergistically leads to a high performance platform for the production of recombinant glycoproteins with uniform Man5- or other human-like glycoforms and superior product yields. Key Features:   Homogeneous, uniform glycoproteins with Man5- or other human-like glycoforms Unrivalled production levels through VTU´s yield enhancing technology platform Production of tailor-made glycoproteins Elimination of hyperglycosylation  Latest Press Releases Evercyte and VTU Technology collaborate on development of recombinant media supplements. VTU Technology and Boehringer Ingelheim strengthen their global microbial technology collaboration. VTU Technology GmbH Parkring 18, 8074 Raaba-Grambach Contact: Dr. Thomas Purkarthofer thomas.purkarthofer@vtu.com Click here to unsubscribe or to change your Subscription Preferences.